Immutep Director’s Interest Update Reflects Strategic Alignment

Immutep Ltd ( (AU:IMM) ) has issued an announcement.

Immutep Limited announced a change in the interest of its director, Lis Boyce, who acquired 707,232 Performance Rights and 166,667 Fully Paid Ordinary Shares. These changes were part of a remuneration package approved at the Annual General Meeting, reflecting the company’s strategy to align director compensation with performance and shareholder interests.

The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.

More about Immutep Ltd

Immutep Limited is a biotechnology company focused on developing immunotherapy treatments. The company specializes in products that modulate the immune system, with a particular emphasis on cancer and autoimmune diseases.

Average Trading Volume: 2,329,094

Technical Sentiment Signal: Sell

Current Market Cap: A$375.3M

For detailed information about IMM stock, go to TipRanks’ Stock Analysis page.